{"id":"5057aea55ff6","type":"article","url":"https://hartvaat.nl/2026/12/01/hypercholesterolemie-in-de-zwangerschap-en-nageboorte-risicos-medicatieveilighei/","title":"Hypercholesterolemie in de zwangerschap en nageboorte: risico’s, medicatieveiligheid en cardio-obstetrische zorg","title_en":"Impact of Hypercholesterolemia on Pregnancy and Postpartum.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":[],"journal":"Obstetrics and gynecology clinics of North America","doi":"10.1016/j.ogc.2026.06.003","source_url":"https://doi.org/10.1016/j.ogc.2026.06.003","authors":["Andrea K Goldstein","Mary Beth Fisher","Vrinda Trivedi","Karen L Florio"],"significance":4,"published":"2026-11-05","source_date":"2026-12-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This narrative review examines the physiological alterations in lipid metabolism during pregnancy and the pathophysiological links between dyslipidemia and adverse maternal and fetal outcomes. It outlines current evidence for risk stratification, medication safety, and monitoring strategies throughout gestation and the postpartum period, emphasizing long-term cardiovascular implications. Integrating lipid management into cardio-obstetric care is essential to address the rising burden of maternal cardiovascular disease.","created":"2026-10-30T02:00:45Z","updated":"2026-10-30T02:00:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Deze narratieve review belicht de fysiologische veranderingen in het lipidenmetabolisme tijdens de zwangerschap en de pathofysiologische link tussen dyslipidemie en ongunstige moeder- en foetale uitkomsten. Het artikel bespreekt strategieën voor risicostratificatie, de veiligheid van lipidumlagerende medicatie tijdens de zwangerschap en het nageboorteperiode, en de lange termijn cardiovasculaire implicaties. Het integreren van lipidomanagement in de cardio-obstetrische zorg helpt om de stijgende maternale sterfte door hart- en vaatziekten tegen te gaan.","abstract_original":"Cardiovascular disease (CVD) is a leading cause of maternal mortality and is secondary to the rising rates of prepregnancy CVD risk factors. Pregnancy represents a unique physiologic state characterized by significant alterations in lipid metabolism, which supports placental steroidogenesis and fetal growth. This article reviews the physiology of lipid metabolism in pregnancy, the pathophysiologic mechanisms linking dyslipidemia to adverse maternal and fetal outcomes, and current evidence guiding clinical management throughout gestation and the postpartum period. Emphasis is placed on risk stratification, medication safety, monitoring strategies, and long-term cardiovascular implications, with the goal of integrating lipid management into contemporary cardio-obstetric care."}